These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Characteristics and outcomes of patients developing pulmonary hypertension associated with proteasome inhibitors. Grynblat J; Khouri C; Hlavaty A; Jaïs X; Savale L; Chaumais MC; Kularatne M; Jevnikar M; Boucly A; Antigny F; Perros F; Simonneau G; Sitbon O; Humbert M; Montani D; Eur Respir J; 2024 Jun; 63(6):. PubMed ID: 38697649 [TBL] [Abstract][Full Text] [Related]
7. Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database. Khouri C; Lepelley M; Roustit M; Montastruc F; Humbert M; Cracowski JL Chest; 2018 Jul; 154(1):136-147. PubMed ID: 29275134 [TBL] [Abstract][Full Text] [Related]
8. Pulmonary arterial hypertension in four patients treated by leflunomide. Coirier V; Lescoat A; Chabanne C; Fournet M; Coiffier G; Jouneau S; Polard E; Jégo P Joint Bone Spine; 2018 Dec; 85(6):761-763. PubMed ID: 29329993 [TBL] [Abstract][Full Text] [Related]
9. Pharmacovigilance in a rare disease: example of the VIGIAPATH program in pulmonary arterial hypertension. Chaumais MC; O'Connell C; Savale L; Guignabert C; Perros F; Jaïs X; Sitbon O; Humbert M; Montani D Int J Clin Pharm; 2018 Aug; 40(4):790-794. PubMed ID: 30101375 [TBL] [Abstract][Full Text] [Related]
10. Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. Jutant EM; Jaïs X; Girerd B; Savale L; Ghigna MR; Perros F; Mignard X; Jevnikar M; Bourlier D; Prevot G; Tromeur C; Bauer F; Bergot E; Dauphin C; Favrolt N; Traclet J; Soumagne T; De Groote P; Chabanne C; Magro P; Bertoletti L; Gueffet JP; Chaouat A; Goupil F; Moceri P; Borie R; Fadel E; Wolkenstein P; Brillet PY; Simonneau G; Sitbon O; Humbert M; Montani D Am J Respir Crit Care Med; 2020 Sep; 202(6):843-852. PubMed ID: 32437637 [No Abstract] [Full Text] [Related]
11. Leflunomide-induced pulmonary hypertension in a young woman with rheumatoid arthritis: a case report. Alvarez PA; Saad AK; Flagel S; Mazzocchi O; Blanco MV Cardiovasc Toxicol; 2012 Jun; 12(2):180-3. PubMed ID: 22270725 [TBL] [Abstract][Full Text] [Related]
12. Leflunomide-induced pulmonary arterial hypertension: Case report and review of literature. Collini V; Driussi M; Nalli C; Baldassi M; Di Poi E; Cereser L; Giuliana F; Patruno V; Stolfo D; Sinagra G; Imazio M J Cardiol Cases; 2022 Aug; 26(2):148-150. PubMed ID: 35949584 [TBL] [Abstract][Full Text] [Related]
13. Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. Chauvelot L; Gamondes D; Berthiller J; Nieves A; Renard S; Catella-Chatron J; Ahmad K; Bertoletti L; Camara B; Gomez E; Launay D; Montani D; Mornex JF; Prévot G; Sanchez O; Schott AM; Subtil F; Traclet J; Turquier S; Zeghmar S; Habib G; Reynaud-Gaubert M; Humbert M; Cottin V Arthritis Rheumatol; 2021 Feb; 73(2):295-304. PubMed ID: 32892515 [TBL] [Abstract][Full Text] [Related]
14. Outcomes of lung disease-associated pulmonary hypertension and impact of elevated pulmonary vascular resistance. Awerbach JD; Stackhouse KA; Lee J; Dahhan T; Parikh KS; Krasuski RA Respir Med; 2019 Apr; 150():126-130. PubMed ID: 30961938 [TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Weatherald J; Boucly A; Chemla D; Savale L; Peng M; Jevnikar M; Jaïs X; Taniguchi Y; O'Connell C; Parent F; Sattler C; Hervé P; Simonneau G; Montani D; Humbert M; Adir Y; Sitbon O Circulation; 2018 Feb; 137(7):693-704. PubMed ID: 29070502 [TBL] [Abstract][Full Text] [Related]
16. Severe pulmonary hypertension associated with COPD: hemodynamic improvement with specific therapy. Girard A; Jouneau S; Chabanne C; Khouatra C; Lannes M; Traclet J; Turquier S; Delaval P; Cordier JF; Cottin V Respiration; 2015; 90(3):220-8. PubMed ID: 26277885 [TBL] [Abstract][Full Text] [Related]
17. Pulmonary Arterial Hypertension-Specific Drug Therapy in COPD Patients with Severe Pulmonary Hypertension and Mild-to-Moderate Airflow Limitation. Calcaianu G; Canuet M; Schuller A; Enache I; Chaouat A; Kessler R Respiration; 2016; 91(1):9-17. PubMed ID: 26492415 [TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics of Patients Undergoing Right Heart Catheterizations in Community Hospitals. Jansen SMA; Huis In 't Veld AE; Tolen PHCG; Jacobs W; Willemsen HM; Grotjohan HP; Waskowsky M; van der Maten J; van der Weerdt A; Hoekstra R; Pérez Matos AJ; Overbeek MJ; Mollema SA; El Bouazzaoui LHH; Vriend JWJ; Roorda JMM; de Nooijer R; van der Lee I; Voogel AJ; Post JC; Macken T; Aerts JM; van de Ven MJT; Bergman H; Bakker-de Boo M; de Boer RC; Vonk Noordegraaf A; de Man FS; Bogaard HJ J Am Heart Assoc; 2022 Sep; 11(17):e025143. PubMed ID: 36062610 [TBL] [Abstract][Full Text] [Related]
20. Association Between Hemodynamic Markers of Pulmonary Hypertension and Outcomes in Heart Failure With Preserved Ejection Fraction. Vanderpool RR; Saul M; Nouraie M; Gladwin MT; Simon MA JAMA Cardiol; 2018 Apr; 3(4):298-306. PubMed ID: 29541759 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]